



# Biotech Daily

Friday August 17, 2012

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH UP: PATRYS UP 15%, ELLEX DOWN 11%**
- \* **EUROPEAN PATENT FOR ANTEO'S MIX&GO BIO-GLUE**
- \* **CONSEGNA APPOINTS CHINAMED FOR BREATHEASSIST MANUFACTURE**
- \* **AMP REDUCES TO 6.35% OF ACRUX**
- \* **CORRECTION: BIO-MELBOURNE BRIEFING**

## MARKET REPORT

The Australian stock market was up 0.92 percent on Friday August 17, 2012 with the S&P ASX 200 up 39.9 points to 4,370.1 points.

Fourteen of the Biotech Daily Top 40 stocks were up, 11 fell, eight traded unchanged and seven were untraded. All three Big Caps fell.

Patrys was the best, up 0.3 cents or 15.0 percent to 2.3 cents with 128,500 shares traded.

Impedimed climbed 8.3 percent; Antisense, Bionomics, Cellmid and Compumedics were up five percent or more; Genetic Technologies, Pharmaxis, Phylogica and Starpharma were up more than four percent; Nanosonics was up 3.2 percent; Mesoblast and QRX rose more than two percent; with Sirtex up 0.7 percent.

Ellex led the falls, down two cents or 10.5 percent to 17 cents with 5,555 shares traded.

Sunshine Heart lost 7.7 percent; Anteo and Prima fell more than four percent; Biota and Living Cell shed more than two percent; Clinuvel, Reva and Tissue Therapies were down more than one percent; with Acrux, Alchemia, Cochlear, CSL and Resmed down by less than one percent.

## ANTEO DIAGNOSTICS

Anteo says the European Patent Office intends to grant a patent entitled 'Use of Metal Complexes' patent for its Mix&Go biological molecule binding technology.

Anteo said there were many commercial reasons to bind biological molecules onto synthetic materials and the molecules were often fragile and did not react well when exposed to non-biological conditions.

The company said the patent covered the intellectual property for the use of Mix&Go to facilitate the binding process and was expected to be granted within three months.

Anteo chief executive officer Dr Geoff Cumming said the Use of Metal Complexes was "a crucial patent and we have now secured it for Mix&Go technology in the US, Japanese, Australian and European markets".

"We are now satisfied with the broad protection we have achieved for our core technology," Dr Cumming said.

"Additional filings were made last year that will offer protection over particular formulations of Mix&Go with unique characteristics that are applicable to some of the different surfaces that we are now working with," Dr Cumming said.

"We were particularly pleased with the European Patent Office allowing our broader claims which provides greater protection as we advance dialogue with large health care companies," Dr Cumming said.

"Anteo is in ongoing discussions with potential commercial partners and this remains the company's core focus for ongoing development," Dr Cumming said.

Anteo fell 0.3 cents or 4.8 percent to six cents with 2.3 million shares traded.

## CONSEGNA

Consegna says it has appointed the US Food and Drug Administration-approved Chinamed to produce its Breatheassist Elite Sport product.

Consegna said Chinamed had operations in the US and China and initial production had begun with first batch of devices expected in Melbourne by mid-September for imminent clinical and consumer trials, a pre-launch sampling campaign and for presentations at sporting and promotional events.

The company said it was preparing for the launch of the Breatheassist Elite Sports product in early 2013.

Consegna managing director Fabio Pannuti said the Breatheassist Elite Sport product was the company's "most advanced product and the imminent launch into the elite sports market is an exciting time".

"Our planning is well advanced for a launch in early 2013 and we continue to get very positive feedback from the athletes currently using Breatheassist Elite Sports," Mr Pannuti said.

Consegna said that Breatheassist was a nasal dilator that increased airflow and the Elite Sports product was designed for athletes.

The company said that Breatheassist was a multi-application platform that enabled products including applications for sleep apnoea, snoring, disorders associated with a deviated septum, drug delivery, odor masking, dust and pollen filtration and enhancing sports performance.

Consegna said the two most advanced applications were for the sports and sleep markets.

Consegna was up 0.1 cents or 8.3 percent to 1.3 cents with 1.9 million shares traded.

### ACRUX

AMP and related bodies have reduced their substantial shareholding in Acrux from 12,352,641 shares (7.42%) to 10,580,495 shares (6.35%).

Acrux fell one cent or 0.2 percent to \$4.10 with 954,708 shares traded.

### BIO-MELBOURNE NETWORK

Last night's edition on the August 22, 2012 Bio-Melbourne Network briefing on "when to sell, when to licence and when to call it quits" incorrectly reported that Inhibitex was acquired by Bristol Myer Squibb for \$2.5 million.

Following a detailed review of the data with the Bio-Melbourne Network, Biotech Daily believes the correct figure should be \$2.5 billion and the write-down was probably, on balance, due to the great big new fat Carbon Tax and a couple of half-starved refugees sailing up the Yarra in the late afternoon.

More information is at: <http://www.biomelbourne.org/events/view/244>.